Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Amgen sheds around 40 staffers amid continuing struggles
(2d)
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
(2d)
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
(2d)
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
(2d)
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
(2d)
BioPharma Dive
Sanofi halts development of troubled immune drug in eczema
(2d)
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
(2d)
Scribe secures $129M in a rare gene editing IPO
(3d)
FDA panel endorses broader use of certain peptides
(3d)
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
(3d)
Endpoints News
Anthropic’s life science plans; Novartis CEO on China deals; and more
(1d)
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
(2d)
Ipsen’s Bylvay fails key trial in children with rare liver disease
(2d)
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
(2d)
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
(2d)
BioSpace
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
(2d)
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
(2d)
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
(2d)
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
(2d)
Roche cans one Carmot obesity asset as another shows best-in-class potential
(2d)
STAT News
I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
(2d)
FDA advisory panel narrowly rejects compounding of one peptide, back another
(2d)
There are already more U.S. measles cases this year than in all of 2025
(2d)
Up and down the ladder: The latest comings and goings
(2d)
Fatal gene-editing trial in China raises ethics and oversight questions
(2d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(3mo)
Drug Channels
Direct-to-Patient: Transforming the Manufacturer Access Model
(2d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
European Biotechnology Magazine
CHMP backs Minoryx’s rare disease drug two years after rejection
(2d)
Sanofi drops eczema drug from $1.1B Kymab deal
(2d)
Iceland-based Synaptiq launches with Nobias’ rare disease drug
(2d)
Fresenius launches €200M healthcare venture fund
(3d)
Neurimmune turns future royalties into $425m pipeline cash
(3d)
Drug Hunter
zidebactam
(2d)
centanafadine
(3d)
thalidomide
(4d)
18F-florquinitau
(5d)
The NaV1.7 Disconnect: Pharmacologic Inhibition Does Not Recapitulate Genetic Loss
(6d)
Labiotech.EU
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(2d)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(2d)
Is an HIV cure possible? The future of HIV therapy
(4d)
Roche’s new gene sequencer on the market: where do current players stand?
(5d)
Inside one of Europe’s most advanced biotech innovation hubs
(5d)
Bio IT World
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(2d)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3d)
Different Teams, Same Problem
(4d)
Winning Best of Show Again: A Reflection on MLADU, Research Data, and the Bio-IT World Community
(5d)
With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform
(1w)
GEN News
Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells
(2d)
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
(2d)
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
(2d)
Single-Cell Maps Reveal Genome Reorganization in Alzheimer’s Brain Cells
(3d)
Autism-Like Traits in Mice Improved After Single Rapamycin Dose
(3d)
Cure Today
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
(1d)
When the Scan Is Over but the Waiting Begins: Living With Lymphoma Scanxiety
(2d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(2d)
Minimally Invasive Options in Rectal Cancer: TAMIS and Robotic Surgery
(3d)
Why I Don’t Want to Hear “You’ll Beat This” After a Metastatic Breast Cancer Diagnosis
(3d)
Contract Pharma
Asymchem Carbapenem API Site in China Successfully Completes First FDA Inspection
(2d)
Federal Equipment Announces Turnkey Sale of Denison Pharmaceuticals Facility
(2d)
Neurocrine Biosciences Names New Senior Vice Presidents
(2d)
The Friday Brief for July 24, 2026: M&A Activity Heating Up
(2d)
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer
(2d)
Pharma Times
GSK wins US approval for ROS1 lung cancer therapy
(3d)
Lundbeck secures FDA Fast Track for narcolepsy drug
(3d)
R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
(4d)
Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
(4d)
Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
(5d)
Medcity News
Candid Health Snags $120M for AI RCM Platform
(8h)
Why Value-Based Care Only Works If You’ve Tamed Costs
(10h)
Medicine Understands Trauma’s Impact, But Rarely Asks About It
(10h)
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility
(1d)
What Health Tech Investors Love in Founders — and What They Can’t Stand
(2d)
Chemical & Engineering News
Rudy Marcus, developer of electron transfer theory, dies at 102
(2d)
ACS continues 150th celebration at EuChemS
(2d)
Policy Watch: DHS puts new limit on international student stays in the US
(2d)
C&EN weekly chemistry news quiz, July 24
(2d)
Ethylene capacity keeps shrinking in South Korea and Japan as Chinese competition mounts
(3d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to July 24, 2026
(13h)
Kaveri Therapeutics
(1d)
India’s pharma M&A market hits four-year high on blockbuster deals
(1d)
FDA approval for first-in-class in ADHD drug Simtriyo
(1d)
July 2026 EMA/CHMP medicines recommended for approval
(2d)
Targeted Oncology
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
(8h)
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
(11h)
Community Clinical Trials and the Lung Cancer Pipeline
(13h)
From Genetic Testing to Personalized Cancer Prevention
(1d)
Ethical Challenges Behind Genome Sequencing and Precision Medicine
(1d)
MedWatch
Novo Nordisk's tablet sales continue to rise following a new subsidy scheme in the US
(2d)
Sanofi discontinues eczema treatment following strategic review
(2d)
Demant grew market share among US veterans in June
(2d)
The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements
(2d)
Genmab fails to meet goals in Phase 3 cancer trial
(2d)
In The Pipeline
Clinical Failure Rates Over the Decades: Yikes
(2d)
The Assault On Science Funding Continues
(3d)
Thoughts on the "Netflix Analogy"
(4d)
Benchmarking the Benchmarks
(5d)
More Pancreatic Cancer Vaccine Progress - Treatment and Preventative
(6d)
Pharmaphorum
Ipsen' Bylvay fluffs its lines in biliary atresia trial
(2d)
Sanofi gives up on amlitelimab in atopic dermatitis
(2d)
Re-rostered FDA committee backs peptide compounding
(2d)
J&J's multiple myeloma duo aces phase 3 trial
(2d)
Dexcom is first to join FDA/CMS health tech pilot
(3d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
HIT Consultant
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
(2d)
Wellumio Closes $9.75M to Commercialize Axana Portable Brain Imaging Device
(2d)
Cigna Healthcare Expands AI-Enabled Care Management to Reach 20% More Customers
(2d)
AdvancedMD Expands Waystar-Powered Revenue Cycle Offerings for Independent Practices
(2d)
Candid Health Secures $120M to Expand Autonomous Revenue Cycle Management Platform
(3d)
Insights: Pink Sheet
Peptide Industry Reaps Six Wins From RFK Jr.-Remade FDA Panel
(2d)
New ADVOCATE Analysis Backs Tavneos Efficacy, Amgen Tells US FDA In Withdrawal Dispute
(2d)
J&J’s Icotyde Nears EU Finish Line As First Oral IL-23 Receptor Drug For Plaque Psoriasis
(2d)
Second Time Lucky: Minoryx Wins EMA Backing For Nezglyal In cALD
(2d)
EMA Opens EU Door For New Cholesterol-Lowering Drugs From NewAmsterdam And LIB
(2d)
BioXconomy
SEC's semiannual reporting proposal debate continues
(2d)
Emerging IP trends for large molecules, CAR-T therapies, and biosimilars
(2d)
Royalty Pharma takes $425m interest in AZ’s cardiovascular drug
(2d)
Crystalys secures $130m to push gout treatment toward market
(3d)
Samsung Biologics makes bold peptide play with $1.8bn PolyPeptide buy
(3d)
BioCentury
Song among trio of new partners at Venrock
(2d)
Hub 101: Taiwan biotech looks to level up
(2d)
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
(2d)
Scribe extends run of strong biotech IPO debuts: Public Equity Report
(2d)
Mapping AI giants’ bets across the biopharma tech stack
(3d)
SCRIP
Novo Nordisk Doubles Down On Efforts To Halt Lilly Tirzepatide Ads
(2d)
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
(2d)
SMID Caps In The Buyer’s Seat
(2d)
Lundbeck Has Busy Spell Ahead For Readouts And Still Shopping For Gems
(2d)
Pipeline Watch: GSK Drops Camlipixant On Mixed CALM Data
(2d)